Kytril

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as an injectable solution for intravenous use. It treats chemotherapy‑induced nausea and vomiting and postoperative nausea and vomiting in patients receiving chemotherapy or undergoing surgery.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Kytril (granisetron) is used to prevent nausea and vomiting mediated by serotonin 5‑HT3 receptors in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed nausea and vomiting in patients receiving emetogenic chemotherapy. - Postoperative nausea and vomiting: helps prevent nausea and vomiting after surgical procedures. - Radiation therapy‑induced nausea and vomiting: alleviates nausea and vomiting associated with therapeutic radiation exposure.

Granisetron may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: reduced bowel movements are reported. - Dizziness: occasional sensation of light‑headedness. - Fatigue: feeling of tiredness or lack of energy.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm, including QT prolongation. - Severe hypotension: marked drop in blood pressure.

When using Kytril, consider the following safety measures.

- Assess risk of QT prolongation: obtain baseline ECG in patients with cardiac risk. - Monitor for allergic reactions: be prepared to treat anaphylaxis promptly. - Use with caution in hepatic impairment: evaluate liver function before administration. - Avoid concomitant use with other 5‑HT3 antagonists unless medically necessary. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Granisetron can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: additive antiemetic effect may increase risk of cardiac events. - QT‑prolonging drugs (e.g., certain antiarrhythmics, antipsychotics): may heighten arrhythmia risk. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise granisetron plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce granisetron effectiveness. - Opioids: may enhance constipation risk when combined with granisetron.